Describing Prostate Cancer Dynamics: Second Look at PSA- Doubling Time and PSA-Specific Growth Rate | IntechOpen
Describing Prostate Cancer Dynamics: Second Look at PSA- Doubling Time and PSA-Specific Growth Rate | IntechOpen
Prostate Cancer Nomograms: PSA Doubling Time | Memorial Sloan Kettering Cancer Center
IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC) | Journal for ImmunoTherapy of Cancer
IJTM | Free Full-Text | Efficacy and Safety of Brazilian Green Propolis in Biochemically Recurrent Prostate Cancer after Radical Prostatectomy: A Single-Arm Phase II Study
Locally Advanced Carcinoma Prostate
Salvage Radiation Therapy Nomograms | Dan's Journey through Prostate Cancer
Oncology Resources - EOS | Emirates Oncology Society
GitHub - conan-koh123/Calculating-PSA-Doubling-Time-for-many-patients: R code to calculate PSA doubling time (in months) for many patients
Describing Prostate Cancer Dynamics: Second Look at PSA- Doubling Time and PSA-Specific Growth Rate | IntechOpen
Describing Prostate Cancer Dynamics: Second Look at PSA- Doubling Time and PSA-Specific Growth Rate | IntechOpen
Impact of 68Ga-Prostate-Specific Membrane Antigen PET/CT on Prostate Cancer Management | Journal of Nuclear Medicine
PSA Doubling Time Calculator
Proposal for a Standardized PSA Doubling-time Calculation | Anticancer Research
Roundtable Discussion: Morgans Addresses How PSA Levels Affect Nonmetastatic CRPC Treatment
Implications of Prostate-Specific Antigen Doubling Time as Indicator of Failure after Surgery or Radiation Therapy for Prostate Cancer - ScienceDirect
Low hemoglobin and PSA kinetics are prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients | Scientific Reports
Time to castration resistance is a novel prognostic factor of cancer-specific survival in patients with nonmetastatic castration-resistant prostate cancer | Scientific Reports
![Tomography | Free Full-Text | [18F]fluciclovine vs. [18F]fluorocholine Positron Emission Tomography/Computed Tomography: A Head-to-Head Comparison for Early Detection of Biochemical Recurrence in Prostate Cancer Patients](https://www.mdpi.com/tomography/tomography-08-00226/article_deploy/html/images/tomography-08-00226-g001.png "Tomography | Free Full-Text | [18F]fluciclovine vs. [18F]fluorocholine Positron Emission Tomography/Computed Tomography: A Head-to-Head Comparison for Early Detection of Biochemical Recurrence in Prostate Cancer Patients")
Tomography | Free Full-Text | [18F]fluciclovine vs. [18F]fluorocholine Positron Emission Tomography/Computed Tomography: A Head-to-Head Comparison for Early Detection of Biochemical Recurrence in Prostate Cancer Patients
Prostate-specific antigen doubling time as a prognostic marker in prostate cancer | Nature Reviews Urology
El tiempo de doblaje de PSA como nuevo método diagnóstico y pronóstico del cáncer de próstata
Risk of Metastasis in Men with Grade Group 2 Prostate Cancer Managed with Active Surveillance at a Tertiary Cancer Center | Journal of Urology
Disease-specific outcomes of Radical Prostatectomies in Northern Norway; a case for the impact of perineural infiltration and postoperative PSA-doubling time | BMC Urology | Full Text
Impact of 68Ga-Prostate-Specific Membrane Antigen PET/CT on Prostate Cancer Management | Journal of Nuclear Medicine
Pathological predictors of 18F‐DCFPyL prostate‐specific membrane antigen‐positive recurrence after radical prostatectomy - Perry - 2022 - BJU International - Wiley Online Library
PSA kinetics impact on CT-PET PSMA uptake in prostate cancer
PDF) Prostate Cancer-Specific Mortality After Radical Prostatectomy for Patients Treated in the Prostate-Specific Antigen Era
